When.com Web Search

Search results

1. Results From The WOW.Com Content Network

2. Some drugmakers to cap cost of asthma inhalers at $35 a month

   www.aol.com/news/drugmakers-cap-cost-asthma...

   Starting Saturday, the cost of inhalers will fall for many Americans, as new out-of-pocket price caps go into effect for the asthma medications from AstraZeneca and Boehringer Ingelheim.

3. If You're Living With Asthma, Here's Every Single Treatment ...

   www.aol.com/youre-living-asthma-heres-every...

   Here’s a fun fact: Ninety percent of people with asthma will develop symptoms of exercise-induced asthma as well, but 10 percent of people with this condition (also referred to as exercise ...

4. Biden, Senator Bernie Sanders push companies to cut cost of ...

   www.aol.com/news/biden-senator-sanders-highlight...

   WASHINGTON (Reuters) -President Joe Biden hosted a White House event with U.S. Senator Bernie Sanders on Wednesday to tout their fight against high prescription drug prices and push companies to ...

5. 340B Drug Pricing Program - Wikipedia

   en.wikipedia.org/wiki/340B_Drug_Pricing_Program

   The 340B Drug Pricing Program is a US federal government program created in 1992 that requires drug manufacturers to provide outpatient drugs to eligible health care organizations and covered entities at significantly reduced prices. The intent of the program is to allow covered entities to "stretch scarce federal resources as far as possible ...

6. Anti-asthmatic agent - Wikipedia

   en.wikipedia.org/wiki/Anti-asthmatic_agent

   An anti-asthmatic agent, also known as an anti-asthma drug, refers to a drug that can aid in airway smooth muscle dilation to allow normal breathing during an asthma attack or reduce inflammation on the airway to decrease airway resistance for asthmatic patients, or both. The goal of asthmatic agents is to reduce asthma exacerbation frequencies ...

7. Prescription drug prices in the United States - Wikipedia

   en.wikipedia.org/wiki/Prescription_drug_prices...

   Drug companies can price new medicines, particularly orphan drugs, i.e. drugs that treat rare diseases, defined in the United States as those affecting fewer than 200,000 patients, at a cost that no individual person could pay, [73] [74] [75] because an insurance company or the government are payors. [76]